AsianScientist (Sep. 6, 2016) – Singapore-based biotech company ASLAN Pharmaceuticals will license a novel immuno-oncology antibody from Singapore’s Agency for Science, Technology and Research (A*STAR).
The antibody targets the macrophage-stimulating protein receptor, which is encoded by the MST1R gene in humans. MST1R is also known as Recepteur d’Origine Nantais (RON) kinase, named after the French city in which it was discovered. When overexpressed, RON has been shown to lead to increased tumor metastasis.
The antibody, which was developed at A*STAR’s p53 Laboratory, has shown pre-clinical efficacy in a range of in vivo models of human cancer. Under the terms of the agreement, ASLAN will gain global rights to develop the antibody; it intends to commence clinical studies in 2018.
To further advance the project towards clinical trials, ASLAN and A*STAR have also entered into a three-year research collaboration. ASLAN will design a clinical development program, while A*STAR’s p53 Laboratory will continue pre-clinical development studies.
———
Source: ASLAN Pharmaceuticals; Photo: ASLAN & A*STAR.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
